Abstract -Spinocerebellar ataxias (SCAs) constitute a heterogeneous group of neurodegenerative diseases characterized by progressive cerebellar ataxia in association with some or all of the following conditions: ophthalmoplegia, pyramidal signs, movement disorders, pigmentary retinopathy, peripheral neuropathy, cognitive dysfunction and dementia. Objective: To carry out a clinical and genetic review of the main types of SCA. Method: The review was based on a search of the PUBMED and OMIM databases. Results: Thirty types of SCAs are currently known, and 16 genes associated with the disease have been identified. The most common types are SCA type 3, or Machado-Joseph disease, SCA type 10 and SCA types 7, 2, 1 and 6. SCAs are genotypically and phenotypically very heterogeneous. A clinical algorithm can be used to distinguish between the different types of SCAs. Conclusions: Detailed clinical neurological examination of SCA patients can be of great help when assessing them, and the information thus gained can be used in an algorithm to screen patients before molecular tests to investigate the correct etiology of the disease are requested.
Spinocerebellar ataxias (SCAs) constitute a large, complex group of heterogeneous autosomal dominant degenerative diseases characterized by progressive degeneration of the cerebellum and its afferent and efferent connections. Other nervous system structures are usually affected, including the basal ganglia, brainstem nuclei, pyramidal tracts and posterior column and anterior horn of the spinal cord, as well as the peripheral nerves [1] [2] [3] [4] [5] [6] [7] [8] . SCAs are clinically characterized by the presence of cerebellar gait and limb ataxia (with dysmetria, dysdiadochokinesia, intention tremor, dysarthria and nystagmus), which may be accompanied by extracerebellar signs such as ophthalmoplegia, pyramidal signs, movement disorders (including parkinsonism, dystonia, myoclonia and chorea), dementia, epilepsy, visual disorders (including pigmentary retinopathy), lower motor neuron disease and peripheral neuropathy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Harding classified SCAs, which had until then been defined as autosomal dominant cerebellar ataxias (ADCAs), into four basic types defined as follows:
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Type 1 is characterized by cerebellar ataxia with optic atrophy, ophthalmoplegia, dementia, amyotrophy and extrapyramidal signs.
Type 2 involves retinal degeneration and can be accompanied by ophthalmoplegia and extrapyramidal signs.
Type 3 can be considered a type of "pure" cerebellar ataxia, while type 4 may present with deafness and myoclonia in addition to the cerebellar ataxia 11 . SCAs have an prevalence of around 1 to 5 cases per 100,000 people 12, 13 . SCA type 3 is the most common form of the disease worldwide; types 1, 2, 6, 7 and 8 have greatly varying prevalences depending on the ethnic background of the population 1, 2, [14] [15] [16] [17] [18] [19] . As a general rule, certain types of spinocerebellar ataxia have a higher incidence in particular countries. Table 1 shows the geographic variation in the prevalence of the main spinocerebellar ataxias in various countries.
In Brazil, Cassa carried out an epidemiologic study in 1996 in which he investigated the prevalence of hereditary ataxias -Machado-Joseph disease (MJD) in particular -in the states of Minas Gerais, São Paulo, Goiás and Espírito Santo. He found that 426 patients in 33 families had SCA, corresponding to a mean incidence of 6.55 cases per 100,000 people (with variations from 0.78 to 228) 20 . In 1997 Lopes-Cendes et al. investigated the frequency of mutations that cause SCAs (SCA1, SCA2, SCA3 and dentatorubral-pallidoluysian atrophy -DRPLA) in a large series of Brazilian patients. They found that a mutation was present in 59% of their cases and that SCA 3 was present in 44% of these, SCA 2 in 9% and SCA 1 in 6% 15 . In 2001 Jardim et al. carried out a study of SCAs in the state of Rio Grande do Sul in which they investigated 66 cases of the disease. The authors concluded that the incidence of MJD found was very high and suggested that this might have been due to the presence of a founder effect of Azorean origin. They estimated the incidence of MJD in the region to be 1.8/100,000 and that of other forms of autosomal dominant ataxia to be 0.2/100,000 17 . In a southern Brazilian series of 100 families with SCAs, a mutation was identified in two-thirds of the cases. SCA 3 was the most frequent form of the disease (73.5%), followed by SCA 10 (11.8%), SCA 2 (7.4%), SCA 7 (4.4%), SCA 1 (2.9%) and SCA 6 (1.5%) 16 . The whole degenerative neuropathological process has been studied in depth in transgenic mice and Drosophila models of SCAs 1, 3, [6] [7] [8] . Neuroimaging, particularly magnetic resonance imaging, reveals cerebellar atrophy, with or without brainstem involvement (olivopontocerebellar atrophy) [1] [2] [3] [4] [5] [6] [7] [8] . The onset of SCAs usually occurs between 30 and 50 years of age; however, cases starting before the age of 20 and after the age of 60 have been described [1] [2] [3] . Current previously unimaginable advances in molecular genetic techniques together with the use of PCR (polymerase chain reaction) have resulted in various genetic loci and genes being identified on different chromosomes, allowing a more rational clinical and genetic classification of the disease [1] [2] [3] 8, [21] [22] [23] [24] . Table 2 shows the main types of SCAs currently known and gives the genetic loci, mutations and proteins associated with the disease.
The phenotypical classification of SCAs described by Harding in 1984 can be compared with the current genotypical classification 8, 11 . Table 3 gives a summary of this comparison. 1, 2, 19, 21, 22 . It should be stressed that SCAs types 9 and 24 remain undefined and that these two type numbers have been reserved for disorders yet to be described in the literature. The mutation in the puratrophin-1(PLEKHG4) gene on chromosome 16q22 is associated with the pure Japanese form of SCA 4 (without sensory axonal neuropathy) and was redefined as SCA 4R. SCA 6 has been identified as being identical to SCA 15. SCA types 29 and 15 and 22 and 19, may represent different allelic forms of the same gene 1, 2, 19 . SCA types 1, 2, 3, 6, 7 and 17 and dentatorubral pallidoluysian atrophy (DRPLA) are caused by mutations in the coding region of the disease gene characterized by the presence of an expanded, unstable polymorphic CAG trinucleotide repeat. The product of the gene is a protein known as ataxin. This protein contains polyglutamine stretches, and these disorders are now known as polyglutamine diseases 8 . The mutant protein ataxin can cause neurodegen- A characteristic that is particular to these types of SCAs is the phenomenon of anticipation, i.e., the increasingly early onset and increasingly severe nature of the clinical picture in successive generations of affected families. The phenomenon of anticipation is related to the number of expanded CAG repeats [1] [2] [3] [5] [6] [7] [8] . A second group of SCAs, which includes SCAs types 8, 10 and 12, is caused by a repeat expansion that is located outside the coding region of the genes associated with the disease and results in deregulation of gene expression 7q31-q32
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(duenas). SCA 8 is associated with a CTG expansion; SCA 10 with a pentanucleotide (ATTCT) repeat; and SCA 12 is caused by deregulation of the activity of protein phosphatase 2 (PP2), an enzyme that has an important function in Purkinje cells [1] [2] [3] . A third group of SCAs -types 5, 11, 13, 14, 15 and 27 -are caused by different mechanisms involving changes in the amino acid composition of the following proteins: βIII spectrin, tau tubulin kinase (TTBK2), potassium channels (KCNC3), protein kinase C (PRKCG), inositol 1,4,5-triphosphate receptor, type 1 (ITPR1) and fibroblast growth factor 14 (FGF14), respectively [1] [2] [3] . Table 4 gives a summary of the normal and expanded nucleotide repeat sequences found in the main types of spinocerebellar ataxias.
SCAs -ThE mOST fREquENT TyPES IN SOuThERN BRAzIL

SCA 3 (Machado-Joseph disease)
This form of autosomal dominant ataxia, which is known as Machado-Joseph disease (MJD), has been described as the most common form of SCA identified in different molecular genetic studies throughout the world 1-3,5-8,14-20,25 . The disease is characterized by a CAG triplet expansion that has been mapped to chromosome 14q32.12 and has from 56 to 86 repeats [1] [2] [3] 8, 16, 17, 25 . Neuropathological features include neuronal loss with reactive gliosis in the following structures: the substantia nigra; the dentate nucleus of the cerebellum; the red nucleus; the pontine nuclei and the nuclei of other motor cranial nerves; Clarke' s column; cells in the anterior horn of the spinal cord; and the spinocerebellar tracts. The globus pallidus can also be affected. Involvement of the olivary nuclei and the cerebellar and cerebral cortex is uncommon [1] [2] [3] [4] [5] 7 . Studies using neuroimaging show the presence of pontocerebellar atrophy, usually without involvement of the olives. However, a study by Murata et al. published in 1998 in which the authors used magnetic resonance imaging also showed the presence of pontocerebellar atrophy and atrophy of the globi pallidi and frontal and temporal lobes 2, 3, 26 . MJD sometimes presents with cerebellar ataxia in association with pyramidal signs; peripheral amyotrophy; nystagmus, ophthalmoparesis and bulging eyes; fasciculations of the face, tongue and occasionally the limbs; and dystonia and parkinsonism [1] [2] [3] [4] [5] [27] [28] [29] . In 1980 Lima and Coutinho proposed the following diagnostic criteria for MJD: autosomal dominant inheritance, major neurological signs: cerebellar ataxia, pyramidal signs, extrapyramidal signs and amyotrophy, minor neurological signs: progressive external ophthalmoplegia, dystonia, fasciculations and bulging eyes 28 . In 1992 Paula Coutinho proposed the following criteria for diagnosing MJD in her PhD thesis: autosomal dominant transmission, onset in adult life, presence of ataxia, supranuclear ophthalmoparesis and pyramidal and extrapyramidal signs, with involvement of the peripheral nervous system, minor signs: fasciculations and bulging eyes, normal higher cortical functions, mean survival of 21 years 30 . SCA 10 SCA 10 was first described in families of Mexican origin. It has well-defined clinical characteristics: patients present with a "pure" cerebellar syndrome, often accompanied by epilepsy and sometimes by peripheral neuropathy 16, 31, 32 . .
The disease-causing mutation that leads to SCA 10 is a large expansion of a pentanucleotide (ATTCT) repeat located in an intron of a gene of unknown function (SCA 10) on chromosome 22q 16, [31] [32] [33] [34] . The DNA test for SCA 10 has 100% sensitivity and specificity and can be performed by PCR or Southern blot analysis. The size of the expanded alleles range from 800 to 4500 ATTCT repeats for a diagnosis of SCA 10 [33] [34] [35] . As a general rule, there is an inverse correlation between age at onset of SCA 10 and the size of the ATTCT repeat expansion [33] [34] [35] . Neuroimaging studies, particularly magnetic resonance imaging of the brain, show the presence of pan-cerebellar atrophy without any abnormalities in other regions 16, 31, 32 . To the author's knowledge there are no descriptions of neuropathological examinations of patients with SCA 10, nor any studies with experimental models. Hence, the mechanism of this type of SCA is completely unknown 16, 31, 32 . In 2001 Rasmunssen et al. published a seminal study in which they described the clinical and genetic analysis of 18 patients in four Mexican families with SCA 10. The mean age at onset among the affected patients was 26.7 years (varying from 14 to 44 years), and the number of AT-TCT repeats varied from 920 to 4140. The authors did not observe any significant anticipation or any correlation between age at onset of the disease and the number of AT-TCT repeats. In addition to cerebellar ataxia and epilepsy (found in 72.2% of the cases), clinical findings included peripheral polyneuropathy in 66% of the cases (confirmed by a nerve conduction study) and cerebellar atrophy, which was predominant in MRI examinations; in some cases mild pyramidal signs, ocular dyskinesia, cognitive dysfunction and/or behavioral disorders were observed, as well as liver, heart and hematological dysfunction 
SCA 7
This type of SCA presents with cerebellar ataxia and progressive visual deficit caused by retinal degeneration (macular dystrophy). It can also be accompanied by pyramidal signs, ophthalmoplegia, parkinsonism and slow saccadic movements in particular [3] [4] [5] [6] . The neuropathological features are olivopontocerebellar degeneration in association with loss of retinal ganglion cells and pigmentary macular dystrophy [3] [4] [5] [6] . The locus of SCA 7 was mapped to chromosome 3 (3p14.1) by David et al. in 1996 . One of the families they studied came from the Crateús region, in Ceará, Brazil 39 . The pathological alleles have between 36 and 306 CAG repeats. The mutant protein, which is known as ataxin 7 and has an unknown function, is expressed in many tissues, including the central nervous system, and only causes selective neuron death in the brain [3] [4] [5] [6] 39 . The clinical picture can emerge from early infancy to the end of the fifth decade and progresses much more quickly in cases involving early onset of the condition. Anticipation may be present in these families [3] [4] [5] [6] 39 . Although a less-common form of SCA, this type is found in various countries and is considered the most common form in Sweden and Finland 3-6,39,40 .
SCA 2 SCA 2 is characterized by cerebellar ataxia accompanied by dysarthria, tremor, hypoactive deep reflexes/arreflexia of the upper and lower limbs (defining the presence of associated peripheral neuropathy), fasciculations of the face and limbs, and characteristic slow saccadic eye movements [3] [4] [5] [6] [7] [8] [9] [10] .
The main clinical characteristic of SCA 2 is the presence of cerebellar ataxia, cerebellar atrophy, which can be observed in neuroimaging examinations, peripheral neuropathy and slow saccadic eye movements. Other clinical manifestations are dystonia, chorea, parkinsonism, myoclonia and dementia [3] [4] [5] [6] [7] [8] [9] [10] . The first description of SCA 2 was by Wadia and Swami, in India in 1971, and the disease was later the subject of considerable study by Orozco in Cuba (Holguín) in 1990 41, 42 . Salem et al., using molecular analysis, studied 42 Indian families with SCA and concluded that SCA 2 was the most common form. The authors also found evidence of a common founding mutation 43 . Basu et al., investigating a series of nine different ethnic populations in India, concluded that SCA 2 was the most common 44 . Velazquez-Perez studied 125 families with SCA in Cuba and concluded that SCA 2 (present in 120 families) was the most common form. There was a high prevalence of this form of the disease in the province of Holguin (70% of the patients), especially in the city of Baguanos (where there was an incidence of 129.2 cases per 100,000 inhab-Spinocerebellar ataxias Teive itants), representing one of the highest rates of SCA in the world. SCA 2 has also been described in other countries with varying frequency 45 . SCA 2 is characterized by cerebellar atrophy, with a loss of Purkinje and granular cells, olivary neurons, substantia nigra and cells in the anterior horn of the spinal cord [3] [4] [5] [6] [7] [8] [9] [10] . The SCA 2 locus has been mapped to chromosome 12 (12q24.13), and the genetic mutation responsible for the disease is a CAG trinucleotide expansion with between 34 and 59 repeats. However, late onset of SCA 2 with a 33 CAG repeat expansion, which is sufficient to cause the disease, has been reported [3] [4] [5] [6] [7] [8] [9] [10] . SCA 2 is characterized by cerebellar ataxia with dysarthria, tremor, hyporeflexia/deep areflexia of the upper and lower limbs (defining the presence of associated peripheral neuropathy), fasciculations of the face and limbs, and characteristic slow saccadic eye movements [3] [4] [5] [6] [7] [8] [9] [10] .
The main clinical characteristic of SCA 2 is its association with cerebellar ataxia (with cerebellar atrophy being observed in neuroimaging examinations), peripheral neuropathy and slow saccadic eye movements. Other clinical manifestations are dystonia, chorea, parkinsonism, myoclonia and dementia [3] [4] [5] [6] [7] [8] [9] [10] . Cognitive deficits have been described in patients with SCA 2 with a frequency of 5 to 19% 46 . SCA 2 is characterized by cerebellar atrophy with a loss of Purkinje and granular cells, olivary neurons, substantia nigra and cells in the anterior horn of the spinal cord [3] [4] [5] [6] [7] [8] [9] [10] . SCA 2 locus has been mapped to chromosome 12 (12q24.13), and the genetic mutation responsible for the disease is a CAG trinucleotide expansion with between 34 and 59 repeats [3] [4] [5] [6] [7] [8] [9] [10] [43] [44] [45] .
SCA 1
Age of onset for SCA 1 is usually after 20 years of age, and the disease manifests itself as gait imbalance, with ataxia (more pronounced in gait than in the limbs), dysarthria, nystagmus, hyperactive deep reflexes and, sometimes, ophthalmoparesia. The most common abnormal eye movement in SCA 1 is a significant increase in the amplitude of saccadic movements, leading to hypermetria. It can occasionally be associated with slow saccadic eye movements, bulbar paralysis, dystonia, chorea and cognitive dysfunction [2] [3] [4] [5] [6] [7] [8] [9] [10] . Pathological examinations show that the systems most affected are the cerebellum (through loss of Purkinje cells and cells in the dentate nucleus), pons, middle cerebellar peduncle and olives 4 . The disease was mapped to chromosome 6 (6p 22.3) -in fact, it was the first ataxia locus ever mapped -and the genetic mutation was defined as an unstable expansion of a repeated CAG sequence (generally between 41 and 81 repeats) [2] [3] [4] [5] [6] [7] [8] [9] [10] .
The number of CAG repeats is related to the age at which signs and symptoms first appear as well as the duration of the disease. In some cases a correlation was found between the pattern of transmission (for example, paternal transmission) and a greater increase in the number of CAG repeats, as well as the phenomenon of anticipation [2] [3] [4] [5] [6] [7] [8] [9] [10] . This form of SCA corresponds to the entity previously described by Schut and Haymaker in 1951 4 . SCA 1 has been detected in 4 to 19% of cases in different series of patients with SCA. However, in some series published to date, it is the most common form of SCA found; in some regions of Italy and Japan, for example, it represents 50% of all cases 2, 4, 7, 8 .
SCA 6
Clinically, this form of SCA is characterized by "pure" cerebellar ataxia, which can be accompanied by dysarthria, nystagmus, dysphagia and even loss of proprioception and dystonia. Many patients have intense episodes of vertigo before the onset of ataxia, while in others there are intermittent episodes of ataxia (corresponding to episodic ataxia type 2) in parallel with the signs and symptoms of slowly progressive cerebellar ataxia 3, 4, 47 . Generally, SCA 6 evolves slowly and progressively, with the clinical picture first appearing around 50 years of age 3, 4, 47 . Neuroimaging reveals cerebellar atrophy, and pathological examination shows a loss of Purkinje cells in the cerebellar cortex as well as gliosis of the inferior olivary complex. Ishikawa et al. described the presence of polyglutamine aggregates in both the nucleus and cytoplasm of Purkinje cells in patients with SCA 6 3, 4, 47 . This SCA is characterized genetically by an expansion of a CAG repeat between 21 and 31 units long in the gene responsible for the voltage-dependent calcium channel known as alpha 1 A (CACNA1A4), which was mapped to chromosome 19p13.13 3, 4, 47 . SCA 6 accounts for between 10 and 30% of all SCAs and is the second most common form of SCA in some series (e.g., in Japan). However, in certain regions of Japan, such as the district of Kinski, this type of SCA is the most common form 1, 3, 4, 47 .
From the clinical point of view, it is particularly important to stress that the SCA 6 mutation is allelic with episodic or sporadic SCA type 2 and hemiplegic migraine 3, 4, 47 .
SCAs -RARE TyPES
SCA 8
This is a new form of SCA characterized by the presence of "pure" cerebellar ataxia that progresses slowly and can be accompanied by eye movement disorder, dysarthria and, less commonly, spasticity, tremor and cogni-Spinocerebellar ataxias Teive tive disorder. Imaging tests reveal cerebellar atrophy, with a relatively preserved brainstem [3] [4] [5] [6] [7] [8] [9] [10] . This type of SCA is unique among the various SCAs, as it has a very complex genetic inheritance pattern. It is characterized genetically by an (extremely variable) CTG expansion that has been mapped to chromosome 13 (13q21). Some patients with CTG allelic expansions never develop the disease, raising doubts about the true pathogenic role of the expansion, i.e., the true relationship between the repeat expansion in the SCA 8 gene and the presence of cerebellar ataxia [2] [3] [4] [5] [6] [7] [8] [9] [10] . SCA 8 is a rare form of SCA and has been described in a small number of cases in various countries, such as Finland, Japan, the USA, Italy, Spain and Scotland 4 .
SCA 12
This form of SCA was described in 1999 by Holmes et al. in a family of German origin known as R. The onset of symptoms usually occurs in the fourth decade of life, with tremor in the upper limbs, and as the disease progresses, gait ataxia, head tremor, dysmetria, hyperactive deep reflexes, abnormal eye movements and, later, dementia. MRI reveals atrophy of the cerebellum and cerebral cortex [3] [4] [5] [6] [7] [8] [9] [10] . The disease was defined to be the result of an expansion of a CAG trinucleotide repeat in the 5' region of the gene complex known as PPP2R2B (mapped to 5q32), which codes for a subunit of the protein phosphatase PP2A 
SCA 17
SCA 17 is a rare form of autosomal neurodegenerative disease caused by an expansion of a CAG triplet repeat in the TBP gene (located in chromosome 6q27), which codes for the TATA binding protein, a transcription initiation factor [1] [2] [3] [4] [51] [52] [53] . The disease was described for the first time in Japan in a 14-year-old female patient whose clinical picture started at the age of 6 years and consisted of gait ataxia, followed later by intellectual deterioration. Parkinsonism and hyperactive deep reflexes can also appear as the disease progresses 4, 52 . SCA 17 is a rare form of autosomal dominant neurodegenerative disease caused by an expansion of a CAG triplet repeat in the TBP gene (located in chromosome 6q27) which encodes for the TATA binding protein, a transcription initiation factor 3, 4, [51] [52] [53] . To date, a number of proven cases of SCA 17 with different clinical presentations have been described. These have a phenotype similar to that of Huntington's disease (Toyoshima et al.) 53 , and with focal dystonia accompanied by cerebellar ataxia and dementia (Hagenah et al.) 54 .
SCAs -VERy RARE TyPES
The SCA types defined as SCA 4, 5, 11, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29 and 30 represent very rare forms and have been diagnosed in a small number of cases in different parts of the world, some of which were only reported in isolated families.
The autosomal dominant form of cerebellar ataxia known as dentatorubral-pallidoluysian atrophy (DRPLA) is a disease with a highly variable phenotype; it was first described in the Japanese, among whom it was reported to have a high incidence, and has been described more recently in African Americans ("Haw River" Syndrome) and Europeans [3] [4] [5] [6] [7] 55 . The disease presents with cerebellar ataxia in association with three different clinical forms: (1) myoclonus epilepsy with dementia; (2) choreoathetosis with dementia (simulating Huntington's disease); and (3) a clinical picture of psychosis, parkinsonism and pyramidal signs 4 . The mutation found in DRPLA is located on chromosome 12 (12p13.31) and consists of an unstable CAG expansion with 49 to 79 repeats that codes for polyglutamine 4, 55 .
SCAS -CLINICAL EVALuATION
SCAs are genotypically and phenotypically very heterogeneous. The presence of phenotypic heterogeneity implies that the same genotype can determine different phenotypes, while genotypic heterogeneity implies that the same phenotype may be the result of a number of genotypes [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The large number of SCAs means that their clinical diagnosis is a difficult task for the clinical neurologist.
Lopes-Cendes et al. published an interesting article about the limitations of clinical evaluation in the correct diagnosis of Machado-Joseph disease. They concluded that although most patients with SCA have common clinical characteristics, the presence of at least two different signs (such as bulging eyes, dystonia or fasciculations of the face and tongue) can help make a clinical diagnosis of MJD possible 56 . Various other authors have suggested that detailed analysis of abnormal eye movements can help identify the main SCAs (types 1, 2, 3 and 6). The main abnormalities, such as changes in the amplitude and speed of saccadic movements, the presence of gaze-evoked nystagmus and impairment of the vestibulo-ocular reflex, are more common in certain types of SCA. For example, slow saccadic movements are more common in SCA 2, gazeevoked nystagmus and vestibulo-ocular reflex dysfunction are more prevalent in SCA 3, and ocular hypermetria more common in SCA 1 4, 57 . Schöls et al. and Garcia Ruiz et al. investigated the presence of movement abnormalities or extrapyramidal signs in patients with hereditary ataxias and concluded that the most common disturbances were parkinsonism, dystonia and postural tremor, which were particularly prevalent in SCAs types 2 and 3 58, 59 . In 2000 Schelhaas et al. published an interesting study of the pathogenesis of different SCAs as well as the phenotypic and genotypic similarities and differences between the diseases 60 . They emphasized the overlap between the phenotypes of the different forms of SCA as well as the great variation that can be observed in each SCA subtype and stated that a diagnosis should be based on genotype analysis. However, they proposed a clinical algorithm to investigate the various SCAs that takes into account different key signs and symptoms, such as retinal degeneration, eye movement disturbances and the presence of pyramidal signs 60 . The information provided above gives a good insight into the difficulties frequently faced in routine neurological clinical practice when assessing patients with SCAs. Such difficulties are a result of the great genotypic heterogeneity (30 known loci and 16 genes already identified) and enormous phenotypic heterogeneity of the disease (as evidenced in MJD, for example).
Hence, it becomes imperative to analyze the frequency of the different forms of SCAs in Brazil as well as the phenotypic and genotypic correlation between them.
It is important to take into account the different neurological signs in patients with SCAs as these could be of value when assessing patients clinically using an algorithm based on clinical data. Such clinical assessment would allow patients to be screened before molecular genetic tests are requested in order to obtain a definitive diagnosis. Table 5 shows a basic algorithm for assessing patients with SCAs.
CONCLuSION
SCAs constitute a large group of neurodegenerative diseases with a high degree of genotypic and phenotypic heterogeneity, making assessment by the clinical neurologist extremely difficult. To date, around 30 types of SCAs are known and 16 genes have been identified. Careful and meticulous clinical assessment of patients with spinocerebellar ataxias can be of significant help in choosing suitable molecular tests to ensure that the etiology is correctly defined. 
